OUHSC Research News – Monday, April 10, 2023

Workshops and Seminars

2023 Innovations in Aging Day

Please join the Oklahoma Dementia Care Network, the OU College of Medicine Section of Geriatrics and Palliative Medicine, and the OU Hudson College of Public Health  for the 2023 Innovations in Aging Day, Tuesday April 18, 2023, 12:15pm to 4pm (virtually), held in conjunction with Careers in Aging WeekThere will be a cash prize ($250) for the 3 best abstracts, plus an invitation to present at the conference!  Click the link below to enter the competition.

Registration link:  https://www.ouhealth.com/events-calendar/event-details/?event=30523

 

OCRID 10th Annual Research Symposium

Date: Tuesday, April 11, 2023, 8:00 AM – 6:00 PM CDT

Location: McKnight Center for the Performing Arts, 705 West University Avenue Stillwater, OK 74074

Description: The Oklahoma Center for Respiratory and Infectious Diseases is a multi-institutional center with investigators coming from Oklahoma State University, University of Oklahoma, and the Oklahoma Medical Research Foundation.

The OCRID Annual Research Symposium provides an opportunity for researchers and students in the fields of respiratory and infectious diseases to gather, network, and learn together from a group of outstanding local and national leaders in their fields. Research disciplines include molecular biology, pathology, animal models, disease pathogenesis, therapeutics, molecular mechanisms, and bioengineering.

The one-day symposium features keynote speakers, showcases the progress of OCRID investigators’ projects and the update from OCRID core facilities, and hosts a poster competition with cash prizes. A catered breakfast, refreshment breaks, and lunch will be provided throughout the day.

Registration and additional information: Please refer to the attached flyers.

 

OUHSC Funding Opportunities

Request for applications:  Genetic CRISPR Screening Pilot Award Program from the Oklahoma Nathan Shock Center on Aging and Oklahoma Center for Therapeutic Sciences

The Oklahoma Nathan Shock Center on Aging (NSC) and the Oklahoma Center for Therapeutic Sciences (CTS) are soliciting proposals for Pilot Awards in target and pathway discovery in cell-based models of aging and age-associated disease using high throughput screening and arrayed sgRNA CRISPR technologies.  Please see the attached RFA for more details.

 

Office of Technology Commercialization presents the following opportunity for researchers to engage with industry (click here for more information, or email otc@ou.edu or gina-mcmillen@ouhsc.edu).  

• Astellas Pharma is seeking research related to direct reprogramming to achieve transdifferentiation of cells to another functional type in order to discover therapeutic interventions for degenerative diseases. Direct reprogramming of cells to cell types related to CNS, Lung, Heart, Kidney, Liver, Gut, Skin and Eye are of particular interest; all methods of in vivo reprogramming considered. Cell therapy, cell transplantation, biomaterial-based therapy and CRISPR/Cas systems are out of scope. Submission entails a 1-pg non-confidential summary of technology with optional supplemental information.  (deadline 4/26).
• Cumulus Oncology is looking to engage with academics who have highly tumor-restricted antigens or moloclonal or multvalent antibodies that target them with potential for therapeutic activity in cancer. Embryonic cell targets are priority but others considered if sufficient tumor-specific activity to minimize off-target effects.  Solid tumors are highest interest but all cancers are within scope.  Out of scope: drug repurposing, small molecule, small antibodies, ADC, immunotoxins, radioimmunotherapy, gene therapy and call based therapeutics.  Submission entails a 1-pg non-confidential summary of technology with optional supplemental information.  (deadline 4/26).
• A global pharmaceutical company is looking to identify novel methods for discovery or design of orally bioavailable peptides and/or peptides that can access intracellular targets through passive permeation, endocytosis or via transporters. Novel in vitro assays for prediction of bioavailability/intracellular targeting with proven translation to in vivo models are also of interest.  Out of scope: use of well-known cell-penetrating peptides (unless significant innovation is demonstrated) and drug delivery systems/formulation strategies.  Submission entails a 1-pg non-confidential summary of technology with optional supplemental information.  (deadline 4/26)
• Worwag Pharma is seeking novel research and technology related to the role of Vitamin D in human health and applications for prevention and treatment of deficiency.  Approaches of interest include metabolites or analogues, novel combinations, approaches with improved metabolism or mode of action, formulations to improve stability and bioavailability, improved drug delivery systems and self-diagnostic tools and digital solutions.  Out of scope: Vitamin D for use in food fortification. Submission entails a 1-pg non-confidential summary of technology with optional supplemental information.  (deadline 5/20)

 

NIH Notices 

• Notice of NIDCD Participation in PAR-21-251 "Emerging Global Leader Award (K43 Independent Clinical Trial Required)" and PAR-21-252 Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed)
  (NOT-DC-23-007)
• Notice of NHLBI Participation in PAR-23-067, Development of Animal Models and Related Biological Materials for Down Syndrome Research (R21 Clinical Trials Not Allowed)
  (NOT-HL-23-084)
• NHLBI Notice of Availability of Frequently Asked Questions (FAQs) for NOT-HL-23-078 and NOT-HL-23-079 (CAROL Act)
  (NOT-HL-23-085)
• Request for Information (RFI) on the NIH Office of Disease Prevention Strategic Plan for Fiscal Years 20242028
  (NOT-OD-23-108)
• Notice of Change to Application and Submission Information in RFA-AI-22-076, Consortium for Food Allergy Research: Clinical Research Center (U01 Clinical Trial Required)
  (NOT-AI-23-043)
• Notice of NIEHS Participation in PAR-23-122 "Research With Activities Related to Diversity (ReWARD) (R01 Clinical Trial Optional)"
  (NOT-ES-23-010)
• Notice of Change to Award Budget in PAR-23-118 "National Centers for Cryoelectron Microscopy (R24 Clinical Trial Not Allowed)"
  (NOT-GM-23-039)
• Notice of Change to Institutional Eligibility Criteria in PAR-22-250 "Centers of Biomedical Research Excellence (COBRE) Phase 1 (P20 - Clinical Trial Optional)"
  (NOT-GM-23-040)
• Notice to Extend the Expiration Date of RFA-HG-22-004: Genome Research Experiences to Attract Talented Undergraduates into Genomic Fields to Enhance Diversity (R25 Clinical Trial Not Allowed)
  (NOT-HG-23-031)
• Notice of Change to Funding Opportunity Implementing and Evaluating New Models for Delivering Comprehensive, Coordinated, Person-Centered Care to People with Long COVID (U18)
  (NOT-HS-23-010)
• Notice of Clarification to Eligibility Criteria for PAR-22-265 "Jointly Sponsored Ruth L. Kirschstein National Research Service Award Institutional Predoctoral Training Program in the Neurosciences (T32 Clinical Trial Not Allowed)"
  (NOT-NS-23-080)
• Notice of Intent to Publish a Funding Opportunity Announcement for Mechanisms of Fusion-Driven Oncogenesis in Childhood Cancers (U01 Clinical Trial Not Allowed)
  (NOT-CA-23-057)
• Notice of Intent to Publish a Funding Opportunity Announcement for Next Generation Chemistry Centers for Fusion Oncoproteins (UM1 Clinical Trial Not Allowed)
  (NOT-CA-23-058)
• Notice of Intent to Publish a Funding Opportunity Announcement for Informatics Tools for the Pangenome (U01 Clinical Trial Not Allowed)
  (NOT-HG-23-028)
• Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: High Quality Reference Genomes (HQRG) (UM1 Clinical Trial Not Allowed)
  (NOT-HG-23-029)
• Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: Human Pangenome Coordinating Center (U41) Clinical Trial Not Allowed
  (NOT-HG-23-030)
• Notice of Special Interest (NOSI): Administrative Supplements to Study the Economics of Cancer Control in Low- and Middle-Income Countries (LMICs)
  (NOT-CA-23-052)
• Notice of Special Interest (NOSI): Leveraging glial cells to treat addiction
  (NOT-DA-24-006)
• Notice of Special Interest (NOSI): Promoting Language and Communication in Minimally Verbal/Non-Speaking Individuals with Autism
  (NOT-DC-23-009)
• Notice of Special Interest (NOSI): Development of Innovative Informatics and Data Science Technologies, Tools, and Methods for Vision Research
  (NOT-EY-23-005)

 

NOTE: When only one application is allowed per Institution according to the sponsor instructions, a one-page letter of intent summarizing the proposed project should be submitted to the Vice President for Research at least two months prior to the application deadline (unless otherwise noted).  The letters of intent will be reviewed and a single application will be chosen for submission from the University.

 

NIH Funding Opportunities

• Enhancing Science, Technology, EnginEering, and Math Educational Diversity (ESTEEMED) Research Education Experiences (R25 Clinical Trial Not Allowed)
  (PAR-23-114)
  Application Receipt Date(s): Multiple dates, see announcement.
• NIH Science Education Partnership Award (SEPA) (R25 - Clinical Trial Not Allowed)
  (PAR-23-137)
  Application Receipt Date(s): Multiple dates, see announcement.
• Limited Competition: NEI - DOD Vision Research Collaborative (R01 Clinical Trial Optional)
  (PAR-23-141)
  Application Receipt Date(s): May 01, 2023
• NIDCR Prospective Observational or Biomarker Validation Study Cooperative Agreement (U01 Clinical Trial Not Allowed)
  (PAR-23-162)
  Application Receipt Date(s): May 07, 2026
• Fundamental Research to Understand the Mechanisms of Neurotropic Virus-mediated Disease (R01 Clinical Trial Not Allowed)
  (RFA-AI-23-028)
  Application Receipt Date(s): August 25, 2023
• Core Centers for Clinical Research (CCCR) (P30 Clinical Trial Not Allowed)
  (RFA-AR-24-003)
  Application Receipt Date(s): September 12, 2023
• Implementation Science for Cancer Control in People Living with HIV in Low- and Middle-Income Countries (U01 Clinical Trial Optional)
  (RFA-CA-23-033)
  Application Receipt Date(s): December 15, 2023
• BRAIN Initiative: Exploratory Research Opportunities Using Invasive Neural Recording and Stimulating Technologies in the Human Brain (R61 Basic Experimental Studies with Humans Required)
  (RFA-DC-24-001)
  Application Receipt Date(s): Multiple dates, see announcement.
• Strategies for Responsibly Reporting Back Environmental Health and Non-Genomic Research Results (R01 Clinical Trial Optional)
  (RFA-ES-23-006)
  Application Receipt Date(s): June 15, 2023
• Implementing and Evaluating New Models for Delivering Comprehensive, Coordinated, Person-Centered Care to People with Long COVID (U18)
  (RFA-HS-23-012)
  Application Receipt Date(s): June 13, 2023
• Developing Measures to Advance Quality in Mental Health Care Services (R01 Clinical Trial Not Allowed)
  (RFA-MH-23-265)
  Application Receipt Date(s): October 10, 2023
• Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Collaborative Research Centers (CRCs) (U54 Clinical Trial Optional)
  (RFA-NS-24-022)
  Application Receipt Date(s): June 15, 2023

 

Other Funding Opportunities

Cystic Fibrosis (CF) Foundation 

• 2023 Spring Research Grant
• 2023 Spring Postdoctoral Research Fellowship
• 2023 Spring Pilot and Feasibility Award  
• 2023 Spring Path to a Cure PTAC) Research Grant 
• 2023 Spring Path to a Cure (PTAC) Postdoctoral Research Fellowship
• 2023 Spring Path to a Cure (PTAC) Pilot and Feasibility Award

Application Deadline: May 11, 2023

 

CF Foundation NIH K-Boost Award

Description: This award is designed to provide a $50,000 per year supplement to an NIH K-award that has a CF focus.

Application Deadline: Rolling applications must be submitted online at awards.cff.org.

For questions, please contact Elizabeth Yu (eyu@cff.org). 

Link to Full Announcement: https://www.cff.org/researchers/cf-foundation-nih-k-boost-award                                                                 

 

CF Foundation/NIH K-Unfunded Award

Description: This award is designed to provide support for investigators with meritorious NIH K applications that were not selected for funding as they revise and resubmit.

Application Deadline: Rolling applications must be submitted online at awards.cff.org.

For questions, please contact Elizabeth Yu (eyu@cff.org). 

Link to Full Announcement: https://www.cff.org/researchers/cf-foundationnih-k-unfunded-award

 

CF Research Additional Mentoring Program (RAMP)

Description: The RAMP Award is designed to enable promising early-career physician scientists seeking additional research mentoring outside of their home academic institutions to enhance their clinical or translational research proficiency and support their development of the necessary clinical research capabilities to become independent investigators.

Application Deadline: Applications must be submitted online at awards.cff.org by May 23, 2023.

For questions, please contact Elizabeth Yu (eyu@cff.org). 

Link to Full Announcement: https://www.cff.org/researchers/research-additional-mentoring-program-award

 

The Lung Cancer Research Foundation (LCRF) – Daiichi Sankyo – AstraZeneca Research Grant on Antibody Drug Conjugates

Description: LCRF is pleased to announce a collaboration with Daiichi Sankyo and AstraZeneca to fund up to three research grants focused on antibody drug conjugates (ADCs) to improve outcomes for people with lung cancer. This competitive funding mechanism will provide up to $270,000 in funding over a two-year period.

The LCRF - Daiichi Sankyo - AstraZeneca Research Grant on Antibody Drug Conjugates will develop further understanding of the mechanism of action and biomarkers for TROP2 directed ADCs in lung cancer and HER2 directed ADCs in HER2 mutant NSCLC and primary and acquired resistance to TROP2 directed and HER2 directed ADCs.

Application Deadline: May 31, 2023

Link to Full Announcement: Complete details including eligibility criteria and application instructions may be found on the LCRF website.

 

Chan Zuckerberg Initiative (CZI) Request for Applications: Ben Barres Early Career Acceleration Award RFA

Description: The Chan Zuckerberg Initiative invites applications for the second cycle of the Ben Barres Early Career Acceleration Awards. This is an investigator award for early career academic investigators, especially those who are new to the field of neurodegeneration. Awards are $1.2M in total costs over 4 years. Early career investigators will benefit from mentored support and resources of the CZI Neurodegeneration Challenge Network.

Letter of Intent (LOI) Deadline: April 20, 2023

Link to Full Announcement: https://chanzuckerberg.com/rfa/ben-barres-early-career-acceleration-awards/

 

Robert A. Winn Career Development Award (Winn CDA)

Description: The goal of the Robert A. Winn Career Development Award (Winn CDA) is to increase the diversity of patients enrolled in clinical trials, and ultimately to enhance the development of therapeutics for all populations. The program collaborates with communities to facilitate an approach to clinical and translational research that is community-informed, designed, and conducted. It provides emerging investigators the sponsorship, support, and tools they need to conduct clinical trials that will yield new treatments effective in all populations.

Application Deadline: May 12, 2023

Link to Full Announcement: https://diversityinclinicaltrials.org/application-information . Please see the attached flyers.

 

HRSA Nurse Education, Practice, Quality and Retention (NEPQR)-Pathway to Registered Nurse Program (PRNP) (HRSA-23-016)

Description: The Health Resources and Services Administration (HRSA) released a new Notice of Funding Opportunity (NOFO). The Nurse Education, Practice, Quality and Retention (NEPQR) - Pathway to Registered Nurse Program (PRNP) aims to create a pathway from academic training to clinical practice through the creation and implementation of Licensed Practical Nurse/Licensed Vocational Nurse (LPN/LVN) to Registered Nurse (RN) Bridge Programs and employment of Clinical Nurse Faculty.

HRSA will award approximately $8.9 million to up to 8 cooperative agreements over a period of four years.

Application Deadline: April 27, 2023

Link to Full Announcement: https://www.hrsa.gov/grants/find-funding/HRSA-23-016?UTM_campaign=NOFO

 

DoD Ovarian Cancer Research Program (OCRP)

• Investigator-Initiated Research Award (IIRA)
• Ovarian Cancer Academy Award - Early-Career Investigator (OCA)
• Pilot Award (PA)

Pre-Application: April 17, 2023

Application: July 21, 2023

• Clinical Translational Research Award
• Clinical Trial Award
• Ovarian Cancer Clinical Trial Academy - Leadership Award

Pre-Application: May 26, 2023

Application: July 21, 2023

Link to Full Announcement: https://cdmrp.health.mil/funding/ocrp

 

DoD Epilepsy Research Program (ERP)

• FY23 ERP Idea Development Award Program Announcement
• FY23 ERP Leveraging Research Award Program Announcement
• FY23 ERP Research Partnership Award Program Announcement
• FY23 ERP Virtual Post-Traumatic Epilepsy Research Center Faculty Award Program Announcement

Pre-Application (Letter of Intent): 5-19-2023

Application: 6-23-2023

Link to Full Announcement: https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=495101

 

DoD Peer Reviewed Medical Research Program (PRMRP)

• FY23 PRMRP Investigator-Initiated Research Award Program Announcement

Pre-Application (Letter of Intent): 4-19-2023

Application: 5-31-2023

• FY23 PRMRP Lifestyle and Behavioral Health Interventions Research Award Program Announcement

Pre-Application (Letter of Intent): 4-19-2023

Application: 5-31-2023

• FY23 PRMRP Technology/Therapeutic Development Award Program Announcement

Pre-Application (Letter of Intent): 4-19-2023

Application: 5-31-2023

Link to Full Announcement: https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=495103

 

The International Center for Responsible Gaming - REQUEST FOR APPLICATIONS ON RESEARCH ON PRE-COMMITMENT AS A PREVENTION MEASURE TO REDUCE GAMBLING-RELATED HARMS

Description: The International Center for Responsible Gaming (ICRG) invites investigators to apply for a two-year Large Grant to study the effectiveness of “pre-commitment,” a prevention strategy that encourages gamblers to set limits on money and time spent gambling. Applicants may request up to a total of $75,000 per year for up to two years plus 15 percent in Facilities & Administration costs. Total amount that may be requested is $172,500.

Application Deadline: May 15, 2023

Link to Full Announcement: https://www.icrg.org/information/apply-for-icrg-funding